

Active patients		
Sex	Classification	Total Sledai
F	ALN	12
M	ALN	4
F	ANLN	8
F	ALN	16
F	ALN	10
F	ALN	14
M	ANLN	8
F	ALN	8
F	ANLN	8
F	ALN	16
F	ALN	8
M	ALN	6
F	ANLN	10
F	ANLN	10
F	ANLN	8
F	ALN	14
F	ALN	8
F	ALN	12
F	ANLN	7
M	ANLN	15
F	ALN	12
F	ALN	16
F	ALN	20
F	ALN	17
F	ALN	24
F	ALN	7
F	ANLN	15
F	ALN	24
F	ALN	32
F	ALN	20
F	ANLN	15
M	ANLN	8
F	ALN	10
M	ALN	22
F	ALN	6
M	ALN	17
M	ALN	20
F	ALN	18
F	ALN	4
M	ANLN	9
F	ANLN	8
M	ALN	22
F	ALN	6
F	ALN	20
F	ALN	5
F	ALN	6
F	ALN	18
F	ALN	6
F	ALN	10

Supplementary Table 1.
 Characteristics of SLE patients
 with active disease.

ALN- active SLE patients with
 nephritis, ANLN- active SLE
 patients with no history of
 nephritis

Supplementary Table 2. Characteristics of SLE patients with quiescent disease.

Remission patients		
Sex	Classification	Total Sledai
F	RNLN	0
F	RLN	0
F	RLN	2
F	RLN	2
F	RLN	0
F	RLN	4
F	RLN	4
F	RNLN	2
F	RLN	0
F	RLN	4
F	RLN	0
F	RLN	4
F	RLN	0
F	RLN	2
F	RLN	2
F	RLN	0
F	RLN	4
F	RLN	4
M	RLN	0
F	RLN	0
F	RLN	2
M	RLN	4
F	RLN	0
F	RLN	2

RLN- patients in remission with a history of nephritis, RNLN- Patients in remission with no history of nephritis

Supplementary Table 3. Characteristics of healthy controls.

Healthy Controls	
Age	Sex
24	F
26	M
24	F
23	F
27	F
23	M
26	M
39	F
25	F
24	M
26	F
37	F
50	F
28	F
29	M
25	M
35	M
57	F
57	F
23	M

Supplementary Table 4.
 Characteristics of SLE patient
 samples collected for FACS
 sorting.

Sex	Disease Duration (years)	Total SLEDAI
F	10	12
F	3	6
M	12	4
F	0.5	12
M	9	8
F	7	6
F	33	4
F	0.67	6
F	1	8
F	7	12
F	1	4
F	12	6
F	3	13
F	0	12
F	0.67	10
F	14	6
F	21	6
F	38	4
F	21	6
F	15	8

Supplementary Table 5.
Characteristics of healthy control
samples collected for FACS
sorting.

Age	Gender
28	F
27	F
39	F
28	M
38	F
21	F
22	F
24	F
38	F
20	F
28	M

Supplementary Table 6

sqPCR primer pairs Mouse		
Primer Name	Forward	Reverse
Actb	AAGAGCTATGAGCTGCCTGA	TACGGATGTCAACGTCACAC
Cyp1a1	CAATGAGTTTGGGGAGGTTACTG	CCCTTCTCAAATGTCCTGTAGTG
Cyp1b1	CCACCAGCCTTAGTGCAGAC	GGCCAGGACGGAGAAGAGT
Il10	ATTTTAATAAGCTCCAAGACCAAGGT	CTGCAGGTGTTTTAGCTTTTCATTT
Tgf β 1	TGGAGCAACATGTGGAACTC	CAGCAGCCGGTTACCAAG
Il6	AGACAAAGCCAGAGTCCTTCAGAGA	GCCACTCCTTCTGTGACTCCAGC
Il12p40	AACTTGAGGGAGAAGTAGGAATGG	GGAAGCACGGCAGCAGAATA
TNF α	TTGAGATCCATGCCGTTGG	ATCATCTTCTCAAATTCGAGTGA
Il1 β	TGTAATGAAAGACGGCACACC	TCTTCTTTGGGTATTGCTTGG
Ido1	TGGCAAACCTGGAAGAAAAAG	AATGCTTTCAGGTCTTGACG
Hmox1	AGCAGAACCCAGTCTATGCCCCA	TGCCAGTGAGGCCCATACCGAA

Supplementary Table 7

sqPCR primer pairs Human		
Primer Name	Forward	Reverse
ACTB	AGAGCTACGAGCTGCCTGAC	AGCACTGTGTTGGCGTACAG
AHR	ATTGTGCCGAGTCCCATATC	AAGCAGGCGTGCATTAGACT
CYP1A1	CTTGGACCTCTTTGGAGCT	GACCTGCCAATCACTGTG
CYP1B1	GACGCCTTTATCCTCTCTGCG	ACGACCTGATCCAATTCTGCC
IFNA1	CTTCAACCTCTTTACCACAAAAGATTC	TGCTGGTAGAGTTCGGTGCA
IFNA2	CTTGAAGGACAGACATGACTTTGGA	GGATGGTTTCAGCCTTTTGGGA
IFNB1	ATGACCAACAAGTGTCTCCTCC	GGAATCCAAGCAAGTTGTAGCTC
IFNG	TCGGTAACTGACTTGAATGTCCA	TCCTTTTTCGCTTCCCTGTTTT
IL10	GACTTTAAGGTTACCTGGGTTG	TCACATGCGCCTTGATGTCTG
IL6	AAATTCGGTACATCCTCGACGG	GGAAGTTTCAGGTTGTTTTCTGC
TGFB1	GGCCAGATCCTGTCCAAGC	GTGGGTTTCCACCATTAGCAC
TNF	TCAGATCATCTTCTCGAACCCC	ATCTCTCAGCTCCACGCCAT

Supplementary Table 8

ChIP sqPCR primers		
Primer Name	Forward	Reverse
Actb	GCTGTGGTGGTGAAGCTGTA	CACACTGTGCCCATCTACGA
Cyp1a1	AGGCTCTTCTCACGCAACTC	CTGGGGCTACAAAGGGTGAT
Cyp1b1	CAGCACTGCCACCAATTCTC	CTGGCGTTCGGTCACTACTC
Ereg	TCCCACCCTTGTATCCCTGAT	CACACACACACACACACACA
Il10	GGTGACTTCCGAGTCAGCAA	ACAGCTATTTTTAGTATGGGCTACC
Il6	CGATGCTAAACGACGTCACATTGTGCA	CTCCAGAGCAGAATGAGCTACAGACAT
IL12p40	ACCGAAGTCCAATGCAAAGG	GGAACACATGCCCACTTGCT
Arg1	TAGTGTCTCCTGGGCATCCT	ACGGGCTTCTGAGGGATTTG
Tgf β 1	CCTCACCTTTATTAGCACACA	AGCTGTTCCTACTGGGAGTTAGC
Ccl2	CCTCAGAGCAGCCAGAAGTG	GCATGGTGGTGGAGGAAGAG
Ccl7	CAAGGCCAGCACAGAGTCT	ACAGAAGCGTGGCAGAGATC
Cxcl5	TTCCCCAGCATCTTCAAGCT	GGAGGAGGTGTGGAGATTGG
Tnf	CGATCACCCCGAAGTTCAGT	GACGTGGAAGTGGCAGAAGA